Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. was founded in 2010 by Yu Qiang, a doctoral student in the United States and a special expert of the "Thousand Talents Plan". It is a high-tech enterprise dedicated to the research, development, production and sales of innovative small molecule drugs. The company has 1000 square meters of research and development experimental site and perfect management system of new drug development company in Suzhou Industrial Park Bio-Nano Park. Since its establishment, the company has applied for a number of invention patents, and has obtained 2 authorized patents. Among them, Shengliptin, a new glucose-lowering drug with a patent, was successfully listed in the national "major new drug development and development" special project during the 12th and 13th five-year plans in 2012 and 2018, indicating that this project has been successfully brought into the track of key support for innovative drugs at the national level. The preclinical study showed that the main technical indicators and long-term benefits of siegliptin were much better than those of its global counterpart, sitagliptin. In 2017, it obtained the clinical approval from the State Food and Drug Administration, and the clinical study began at the end of 2017. Suntec's flash release technology has also been awarded the title of Suzhou Engineering Center. On this platform, we have developed new drug projects for special preparations represented by axenapine. In the future, more class 2 improved drugs,505(b)2, will be developed based on this platform. In addition, since 2014, the company has made use of its own technical advantages to actively provide research and development services. In recent years, the sales volume has reached the level of 10 million yuan, and the company has obtained the strategic initiative for the survival and development of the enterprise. The company has received clinical approval for three drug classes, including asenapine maleate, terfluramide, votioxetine, and berlinostat. The company has been constantly receiving strong support and full recognition from the park, Suzhou City and Jiangsu Provincial Government and the country, and has obtained financial support and honor for many projects. Moreover, the company is actively financing, which provides a solid financial guarantee for the company's new drug development projects. Most of the members of the entrepreneurial team have successful entrepreneurial experience and the ability to fully accept challenges. They lead more than 40 employees of the company to achieve the company's goal of becoming a leader in drug research and development in China in the future with novel pharmaceutical concepts, leading technologies and practical business plans.

Registered Capital:  

Registered Address:  Room 101, 102, C11 / F, Bio-Nano Park, No. 218, Xinghu Street, Suzhou Industrial Park

Company Type:  Production

Business Scope: